mRNA vaccine for cancer immunotherapy
Top Cited Papers
Open Access
- 25 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 20 (1), 1-23
- https://doi.org/10.1186/s12943-021-01335-5
Abstract
MRNA vaccines have become a promising platform for cancer immunotherapy. During vaccination, naked or vehicle loaded mRNA vaccines efficiently express tumor antigens in antigen-presenting cells (APCs), facilitate APC activation and innate/adaptive immune stimulation. mRNA cancer vaccine precedes other conventional vaccine platforms due to high potency, safe administration, rapid development potentials, and cost-effective manufacturing. However, mRNA vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery. Appropriate mRNA structure modifications (i.e., codon optimizations, nucleotide modifications, self-amplifying mRNAs, etc.) and formulation methods (i.e., lipid nanoparticles (LNPs), polymers, peptides, etc.) have been investigated to overcome these issues. Tuning the administration routes and co-delivery of multiple mRNA vaccines with other immunotherapeutic agents (e.g., checkpoint inhibitors) have further boosted the host anti-tumor immunity and increased the likelihood of tumor cell eradication. With the recent U.S. Food and Drug Administration (FDA) approvals of LNP-loaded mRNA vaccines for the prevention of COVID-19 and the promising therapeutic outcomes of mRNA cancer vaccines achieved in several clinical trials against multiple aggressive solid tumors, we envision the rapid advancing of mRNA vaccines for cancer immunotherapy in the near future. This review provides a detailed overview of the recent progress and existing challenges of mRNA cancer vaccines and future considerations of applying mRNA vaccine for cancer immunotherapies.Keywords
Funding Information
- National Institutes of Health (CA198999)
This publication has 149 references indexed in Scilit:
- Overcoming HLA restriction in clinical trialsOncoImmunology, 2012
- Nonviral delivery of self-amplifying RNA vaccinesProceedings of the National Academy of Sciences of the United States of America, 2012
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie, 2012
- Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activationVirology, 2012
- Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus InvasionJournal of Virology, 2012
- Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNAMolecular Therapy Nucleic Acids, 2012
- Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNANucleic Acids Research, 2011
- RNA Replicons - A New Approach for Influenza Virus ImmunoprophylaxisViruses, 2010
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008